NCT05955586 is a Phase 1 clinical trial of SPR720 in Healthy Volunteer, sponsored by Spero Therapeutics.

Who is sponsoring NCT05955586?

NCT05955586 is sponsored by Spero Therapeutics.

What drugs are being tested in NCT05955586?

Interventions in NCT05955586: SPR720.

What condition does NCT05955586 study?

NCT05955586 studies Healthy Volunteer.

Is NCT05955586 still recruiting?

NCT05955586 is currently completed. Last updated 7 March 2024.

Last reviewed 2024-03-07 · How we verify

NCT05955586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

Completed Phase 1 Last updated 7 March 2024

What this trial tests

Phase 1 trial testing SPR720 in Healthy Volunteer in 33 participants. Completed in 23 February 2024.

Timeline

1 August 2023

Primary endpoint
9 February 2024

23 February 2024

Quick facts

Lead sponsor	Spero Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 August 2023
Primary completion	9 February 2024
Estimated completion	23 February 2024
Sites	1 location across United States

Drugs / interventions tested

SPR720 — full drug profile →

Conditions studied

Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

Spero Therapeutics — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to evaluate the intrapulmonary PK, including epithelial lining fluid (ELF) and alveolar macrophages (AM) concentrations, of SPR719 compared to plasma concentrations of SPR719 (the active moiety in plasma of the prodrug SPR720) after oral administration of SPR720 1000 milligram (mg) capsules every 24 hours for 7 consecutive doses.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon.
Kufa M, Finger V, Kovar O, Soukup O, et al · · 2025 · cited 6× · PMID 40370552 · DOI 10.1016/j.apsb.2025.01.023
<i>M. avium Complex</i> Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development.
Charrier ESA, Dassonville-Klimpt A, Andréjak C, Sonnet P. · · 2025 · cited 2× · PMID 40573286 · DOI 10.3390/ph18060891
Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.
Rodvold KA, Gotfried MH, Ussery XT, Wong SL, et al · · 2024 · cited 2× · PMID 39352135 · DOI 10.1128/aac.01103-24

Verify or expand the search:

Other trials of SPR720

Trials testing the same drug.

NCT05966688 — A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in H · Phase 1 · completed
NCT04553406 — Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Com · Phase 2 · terminated

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting

Other Spero Therapeutics trials

Trials by the same sponsor.

NCT06727136 — A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its M · Phase 1 · completed
NCT06059846 — A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants · Phase 3 · completed
NCT05966688 — A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in H · Phase 1 · completed
NCT05856747 — A Study to Compare Two Bioanalytical Assays for Tebipenem · Phase 1 · completed
NCT05496374 — A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05955586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spero Therapeutics
Last refreshed: 7 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05955586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing